source
- J&J dips despite upbeat outlook; AstraZeneca, Spero cut China dealsJ&J’s shares ticked down as oncology sales missed expectations. Elsewhere, AstraZeneca bet $600 million on a lung cancer drug and a pair of biotechs snagged two of the year’s top venture rounds.BioPharma Dive · 15d ago↗ source
- Diamantas backtracks on Makary’s policies issued in journal articlesThe acting commissioner of the US Food and Drug Administration (FDA) has clarified that certain policies disseminated in medical journals by former FDA Commissioner Marty Makary are not official ag…raps · 16d ago↗ source
- CVS Caremark reaches settlement with FTC over insulin suitTerms of the deal announced Tuesday are very similar to those the FTC reached with Express Scripts earlier this year, including requiring the PBM to stop preferring higher cost versions of drugs on…